A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Eli Lilly and Company
787 participants
May 20, 2025
INTERVENTIONAL
Conditions
Summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Eligibility
Inclusion Criteria1
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Interventions
Administered orally.
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06876649